Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$562.05 USD

562.05
62,873

+3.78 (0.68%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $563.01 +0.96 (0.17%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 9th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Tirthankar Chakraborty headshot

5 Low-Risk Stocks to Buy for Epic Price Swings Since 1929

by Tirthankar Chakraborty

The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.

Nalak Das headshot

Market to Stay Northbound Despite Volatility: 5 Growth Picks

by Nalak Das

Although, short-term fluctuations will continue on account of the coronavirus-induced crisis, overall market movement will remain positively sloped.

Catasys (CATS) Looks Good: Stock Adds 9.2% in Session

by Zacks Equity Research

Catasys (CATS) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off

by Zacks Equity Research

This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.

Why Is Chemed (CHE) Down 28.5% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Grows Internationally, Hereditary Cancer Revenues Soft

by Zacks Equity Research

Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.

Medtronic to Boost Ventilator Capacity to Combat Coronavirus

by Zacks Equity Research

When all other major business segments of Medtronic (MDT) are facing recessionary hurdles, the company's latest move is anticipated to aid its Minimally Invasive Therapies Group business.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on its strong segmental and international results in the fourth quarter of 2019.

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.

Chemed (CHE) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CHE) Outperforming Other Medical Stocks This Year?

How Chemed (CHE) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Chemed (CHE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Risk-Averse Investors May Buy These 5 Low Leverage Stocks

by Zacks Equity Research

Since a debt-free company is rare to find, measuring the debt level of a company is an important point of consideration while making an investment decision.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 20th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

Bet on These 5 Low Leverage Stocks to Escape a Debt Trap

by Zacks Equity Research

Exorbitant debt financing might lead to a corporation's bankruptcy in the worst-case scenario. Since a debt-free company is rare to find, we should focus on those carrying low debt levels

Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed

by Zacks Equity Research

Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed

Buy These 5 Low Leverage Stocks This Earnings Season

by Zacks Equity Research

With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.

Icon PLC (ICLR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

by Zacks Equity Research

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Chemed (CHE) could produce exceptional returns because of its solid growth attributes.